Olivier Brandicourt to leave Bayer HealthCare

23-Feb-2015 - Effective March 31, 2015, Olivier Brandicourt (59), Chairman of the Board of Management of Bayer HealthCare AG and member of the Executive Council of Bayer AG, will leave the company to become new CEO of Sanofi as of April 2, 2015. On the same date, Werner Baumann (52), member of the Board of ...

Dieter Weinand to become President of Bayer HealthCare Pharmaceuticals

06-Jun-2014 - Dieter Weinand (53), President Global Commercialization & Portfolio Management at Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA, will become President of Bayer HealthCare Pharmaceuticals effective August 1, 2014 and at the same time join the Executive Committee of ...

arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates

02-Jun-2014 - arGEN-X announced the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic ...

Andreas Fibig to leave Bayer HealthCare Pharmaceuticals

30-May-2014 - Andreas Fibig (52), President of Bayer HealthCare Pharmaceuticals and a member of the Bayer HealthCare Executive Committee, will leave Bayer HealthCare to become Chief Executive Officer of International Flavors & Fragrances Inc., New York, NY, USA, effective September 1, 2014. "With his ...

Bayer to divest Interventional device business for $415 million

19-May-2014 - Bayer HealthCare has entered into a definitive agreement to sell its Interventional device business to Boston Scientific. The total consideration for the transaction, including fees for transitional services, is $415 million (about EUR 300 million). The sale will include the AngioJet™ ...

Bayer’s Riociguat submitted for regulatory approval in the U.S. and EU

12-Feb-2013 - Bayer HealthCare has submitted the oral investigational drug Riociguat to treat patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) for regulatory approval in the United States and in the European Union. “These regulatory ...

QIAGEN and Bayer HealthCare partner to develop companion diagnostics to guide treatment decisions for targeted cancer therapies

26-Oct-2012 - QIAGEN and Bayer HealthCare announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular ...

Anti-Cancer Project Originating from LDC Reaches Next Milestone

Successful Transfer into Pre-Clinical Drug Development at Bayer Pharma AG

24-Sep-2012 - The Lead Discovery Center GmbH (LDC) announced that a kinase inhibitor program licensed to Bayer Pharma AG, Germany (Bayer) last year, has reached an important transition milestone. Bayer has successfully advanced this kinase inhibitor program into pre-clinical development with the goal of ...

Horizon Discovery and Bayer Collaborate to Develop Cell Line Models to Support Oncology Programs

12-Jul-2012 - Horizon Discovery Ltd announced it has signed a collaboration agreement with Bayer Pharma AG (Bayer) to develop preclinical cell line models that will support Bayer’s oncology research and development programs, using Horizon’s precision genome editing technology, GENESIS™. The aim of the ...

Dr. Dirk Ehle appointed Head of Bayer HealthCare's Animal Health Division

30-Apr-2012 - Dr. Dirk Ehle has been appointed Head of the Animal Health Division of Bayer HealthCare AG effective May 1, 2012. The 42-year-old succeeds Dr. Jean-Luc Lowinski, who is leaving the company at his own request. As divisional head, Ehle will also be member of the Bayer HealthCare Executive ...